



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

November 2004

BEST AVAILABLE COPY

Patents Form 1/77

Patents Act 1977
(Rule 16)

The
Patent
Office

THE PATENT OFFICE
JR

13 OCT 2003
RECEIVED BY FAX

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP9 1RH

1. Your reference

P103161GB

2. Parent application number

(The Patent Office will fill in this part)

0323813.6

13OCT03 E843812-1 D02973

P01/7700 0.00-0323813.6

13 OCT 2003

3. Full name, address and postcode of the or of each applicant (underline all surnames)

The University of York
Heslington
York
YO1 5DD
GB

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

7245376004

4. Title of the invention

Glucosyltransferases

5. Name of your agent (if you have one)

Harrison Goddard Foote

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

31 St Saviourgate
YORK
YO1 8NQ

Patents ADP number (if you know it)

07914237002 ✓

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if

a) any applicant named in part 3 is not an inventor, or yes

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

Patents Form 1/77

0082572 13-Oct-03 08:53

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description 15

Claim(s) 5

Abstract 1

Drawing(s) 8-7

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 8/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date

13.10.03

12. Name and daytime telephone number of person to contact in the United Kingdom

Rob Docherty

01904 732120

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
b) Write your answers in capital letters using black ink or you may type them.
c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
e) Once you have filled in the form you must remember to sign and date it.
f) For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

DUPLICATE

GLUCOSYLTRANSFERASES

5 The invention relates to transgenic cells which have been transformed with nucleic acid molecules which encode glucosyltransferases (GTase) which glycosylate monolignols which are intermediates in lignin biosynthesis.

10 GTases are enzymes which post-translationally transfer glucosyl residues from an activated nucleotide sugar to monomeric and polymeric acceptor molecules such as other sugars, proteins, lipids and other organic substrates. These glucosylated molecules take part in diverse metabolic pathways and processes. The transfer of a glucosyl moiety can alter the acceptor's bioactivity, solubility and transport properties within the cell and throughout the plant. One family of GTases in higher plants is
15 defined by the presence of a C-terminal consensus sequence. The GTases of this family function in the cytosol of plant cells and catalyse the transfer of glucose to small molecular weight substrates, such as phenylpropanoid derivatives, coumarins, flavonoids, other secondary metabolites and molecules known to act as plant hormones.

20 Wood used in the paper industry is initially particulated, typically by chipping, before conversion to a pulp which can be utilised to produce paper. The pulping process involves the removal of lignin. Lignin is a major non-carbohydrate component of wood and comprises approximately one quarter of the raw material in wood pulp.
25 The removal of lignin is desirable since the quality of the paper produced from the pulp is largely determined by the lignin content. Many methods have been developed to efficiently and cost effectively remove lignin from wood pulp. These methods can be chemical, mechanical or biological. For example, chemical methods to pulp wood are disclosed in WO9811294, EP0957198 and WO0047812. Although chemical
30 methods are efficient means to remove lignin from pulp it is known that chemical treatments can result in degradation of polysaccharides and is expensive. Moreover, to remove residual lignin from pulp it is necessary to use strong bleaching agents which require removal before the pulp can be converted into paper. These agents are also damaging to the environment.

35

Biological methods to remove lignin are known, but have inherent disadvantages. For example it is important to provide micro-organisms (e.g. bacteria and/or fungi) which only secrete ligninolytic enzymes which do not affect cellulose fibres. This method is also very time consuming (can take 3-4 weeks) and expensive due to the need to provide bioreactors. Biological treatment can also include pre-treatment of wood chips to make them more susceptible to further biological or chemical pulping.

In some applications, for example the construction industry or in furniture making, it may be desirable to increase the lignin content of a plant cell to increase the mechanical strength of wood.

Both lignin content and the level of cross-linking of polysaccharide polymers within plant cell walls, also play an important role in determining texture and quality of raw materials through altering the cell walls and tissue mechanical properties. For example, there is considerable interest in reducing cell separation in edible tissues since this would prevent over-softening and loss of juiciness. Phenolics, such as ferulic acid, play an important role in cell adhesion since they can be esterified to cell wall polysaccharides during synthesis and oxidatively cross-linked in the wall, thereby increasing rigidity. Most non-lignified tissues contain these phenolic components and their levels can be modified by altering flux through the same metabolic pathways as those culminating in lignin. Therefore, in the same way as for the manipulation of lignin composition and content, GTase nucleic acid in sense and/or antisense configurations can be used to affect levels of ferulic acid and related phenylpropanoid derivatives that function in oxidative cross-linking. These changes in content have utility in the control of raw material quality of edible plant tissues.

Lignin and oxidative cross-linking in plant cell walls also play important roles in stress and defence responses of most plant species. For example, when non-woody tissues are challenged by pests or pathogen attack, or suffer abiotic stress such as through mechanical damage or UV radiation, the plant responds by localised and systemic alteration in cell wall and cytosolic properties, including changes in lignin content and composition and changes in cross-linking of other wall components. Therefore, it can also be anticipated that cell- or tissue-specific changes in these

responses brought about by changed levels of the relevant GTase activities will have utility in protecting the plant to biotic attack and biotic/abiotic stresses.

5 GTases also have utility with respect to the modification of antioxidants. Reactive oxygen species are produced in all aerobic organisms during respiration and normally exist in a cell in balance with biochemical anti-oxidants. Environmental challenges, such as by pollutants, oxidants, toxicants, heavy metals and so on, can lead to excess reactive oxygen species which perturb the cellular redox balance, potentially leading to wide-ranging pathological conditions. In animals and humans, cardiovascular diseases, cancers, inflammatory and degenerative disorders are linked to events arising from oxidative damage.

15 Because of the current prevalence of these diseases, there is considerable interest in anti-oxidants, consumed in the diet or applied topically such as in UV-screens. Anti-oxidant micronutrients obtained from vegetables and fruits, teas, herbs and medicinal plants are thought to provide significant protection against health problems arising from oxidative stress. Well known anti-oxidants from plant tissues include for example: quercetin, luteolin, and the catechin, epicatechin and cyanidin groups of compounds.

25 Certain plant species, organs and tissues are known to have relatively high levels of one or more compounds with anti-oxidant activity. Greater accumulation of these compounds in those species, their wider distribution in crop plants and plant parts already used for food and drink production, and the increased bioavailability of anti-oxidants (absorption, metabolic conversions and excretion rate) are three features considered to be highly desirable.

30 The identity of a number of glucosyltransferase genes involved in lignin biosynthesis within *Arabidopsis* have been described in Lim *et al.* 2001. The isolation and characterisation of two of these genes, 72E2 and 72E3, both members of a small subfamily within Group E of the phylogenetic tree of *Arabidopsis* UGTs, were further disclosed in WO01/59140. The UGTs encoded by these genes glycosylate the metabolites of the phenylpropanoid pathway by the transfer of glucose from UDP-

glucose to a hydroxyl group on the metabolite. This leads either to the formation of a glucose ester. The identification and characterisation of 72E2 and 72E3 led to the ability, via regulating gene expression, to be able to modulate the extent of lignification within a plant, thereby altering the mechanical properties, responsiveness to wounding and pathogen stress and xenobiotic de-toxification ability of the plant. We disclose a further sequence involved in glycosylation of metabolites in the phenylpropanoid pathway which alone or in combination with 72E2 and 72E3 modulate lignin biosynthesis.

10 According to an aspect of the invention there is provided a transgenic cell wherein the genome of said cell comprises a nucleic acid molecule wherein said nucleic acid molecule is selected from the group consisting of;

- i) a nucleic acid molecule comprising a nucleic acid sequence as represented in Figure 1;
 - 15 ii) a nucleic acid molecule comprising a nucleic acid sequence which hybridises to the sequence in (i) above and which glucosylates at least one monolignol;
 - iii) a nucleic acid molecule comprising a nucleic acid sequences which are degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above.
- 20

In a preferred embodiment of the invention said aldehyde of a monolignol is selected from the group consisting of; *p*-coumaryl aldehyde, coniferyl aldehyde and sinapyl aldehyde.

25

In an alternative preferred embodiment of the invention said monolignol is coniferyl alcohol.

30 Preferably said hybridisation is stringent hybridisation. Stringent hybridisation/washing conditions are well known in the art. For example, nucleic acid hybrids that are stable after washing in 0.1xSSC, 0.1% SDS at 60°C. It is well known in the art that optimal hybridisation conditions can be calculated if the sequence of the nucleic acid is known. For example, hybridisation conditions can be determined by the GC content of the nucleic acid subject to hybridisation.

In a further preferred embodiment of the invention said nucleic acid is cDNA.

In a yet further preferred embodiment of the invention said nucleic acid is genomic
5 DNA.

In a preferred embodiment of the invention said nucleic acid molecule comprises a
nucleic acid sequence as shown in Figure 1. Preferably said nucleic acid molecule
consists of a nucleic acid sequence as shown in Figure 1.
10

In a further preferred embodiment of the invention said nucleic acid molecule is over
expressed.

In a preferred embodiment of the invention said over-expression is at least 2-fold
15 higher when compared to a non-transformed reference cell of the same species.
Preferably said over-expression is: at least 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold,
9-fold, or at least 10-fold when compared to a non-transformed reference cell of the
same species.

20 In a further preferred embodiment of the invention said cell over-expresses a nucleic
acid molecule selected from the group consisting of:

- i) a nucleic acid molecule comprising a nucleic acid
sequence as represented in Figure 1 and Figure 3 and/or
Figure 5;
- 25 ii) a nucleic acid molecule comprising a nucleic acid
sequence which hybridises to the sequence in (i) above
and which glucosylates at least one monolignol;
- iii) a nucleic acid molecule comprising a nucleic acid
sequences which are degenerate as a result of the genetic code to
30 the sequences defined in (i) and (ii) above.

In an alternative preferred embodiment of the invention said cell over-expresses a
nucleic acid molecule as represented by the nucleic acid sequence shown in Figure 3

and Figure 5, or a nucleic acid molecule which hybridises to a nucleic acid molecule as represented by the nucleic acid sequence in Figure 3 and Figure 5.

5 This over expression may be as a result of an increased copy number of said nucleic acid molecule. Alternatively said nucleic acid sequence may be operably linked to a heterologous promoter.

A vector comprising the nucleic acid molecule operably linked to a heterologous promoter would be used to transfect/transform a selected cell.

10

"Vector" includes, inter alia, any plasmid, cosmid, phage or Agrobacterium binary vector in double or single stranded linear or circular form which may or may not be self-transmissible or mobilizable, and which can transform a prokaryotic or eukaryotic host either by integration into the cellular genome or exist extrachromosomally (e.g. autonomous replicating plasmid with an origin of replication is an episomal vector).

15

Suitable vectors can be constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. For further details see, for example, Molecular Cloning: Laboratory Manual: 2nd edition, Sambrook et al. 1989, Cold Spring Harbor Laboratory Press or Current Protocols in Molecular Biology, Second Edition, Ausubel et al. Eds., John Wiley & Sons, 1992.

20

Specifically included are shuttle vectors by which is meant a DNA vehicle capable, naturally or by design, of replication in two different host organisms, which may be selected from actinomycetes and related species, bacteria and eukaryotic (e.g. higher plant, mammalian, yeast or fungal cells).

25

A vector including nucleic acid according to the invention need not include a promoter or other regulatory sequence, particularly if the vector is to be used to introduce the nucleic acid into cells for recombination into the gene.

30

Preferably the nucleic acid in the vector is under the control of, and operably linked to, an appropriate promoter or other regulatory elements for transcription in a host cell

such as a microbial, (e.g. bacterial), or plant cell. The vector may be a bi-functional expression vector which functions in multiple hosts. In the case of GTase genomic DNA this may contain its own promoter or other regulatory elements and in the case of cDNA this may be under the control of an appropriate promoter or other regulatory elements for expression in the host cell.

By "promoter" is meant a nucleotide sequence upstream from the transcriptional initiation site and which contains all the regulatory regions required for transcription. Suitable promoters include constitutive, tissue-specific, inducible, developmental or other promoters for expression in plant cells comprised in plants depending on design. Such promoters include viral, fungal, bacterial, animal and plant-derived promoters capable of functioning in plant cells.

Constitutive promoters include, for example CaMV 35S promoter (Odell et al. (1985) Nature 313, 9810-812); rice actin (McElroy et al. (1990) Plant Cell 2: 163-171); ubiquitin (Christian et al. (1989) Plant Mol. Biol. 18 (675-689); pEMU (Last et al. (1991) Theor Appl. Genet. 81: 581-588); MAS (Velten et al. (1984) EMBO J. 3. 2723-2730); ALS promoter (U.S. Application Serial No. 08/409,297), and the like. Other constitutive promoters include those in U.S. Patent Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785; 5,399,680, 5,268,463; and 5,608,142.

Chemical-regulated promoters can be used to modulate the expression of a gene in a plant through the application of an exogenous chemical regulator. Depending upon the objective, the promoter may be a chemical-inducible promoter, where application of the chemical induced gene expression, or a chemical-repressible promoter, where application of the chemical represses gene expression. Chemical-inducible promoters are known in the art and include, but are not limited to, the maize In2-2 promoter, which is activated by benzenesulfonamide herbicide safeners, the maize GST promoter, which is activated by hydrophobic electrophilic compounds that are used as pre-emergent herbicides, and the tobacco PR-1a promoter, which is activated by salicylic acid. Other chemical-regulated promoters of interest include steroid-responsive promoters (see, for example, the glucocorticoid-inducible promoter in Schena et al. (1991) Proc. Natl. Acad. Sci. USA 88: 10421-10425 and McNellis et al. (1998) Plant J. 14(2): 247-257) and tetracycline-inducible and tetracycline-repressible

promoters (see, for example, Gatz et al. (1991) *Mol. Gen. Genet.* 227: 229-237, and US Patent Nos. 5,814,618 and 5,789,156, herein incorporated by reference.

Where enhanced expression in particular tissues is desired, tissue-specific promoters can be utilised. Tissue-specific promoters include those described by Yamamoto et al. (1997) *Plant J.* 12(2): 255-265; Kawamata et al. (1997) *Plant Cell Physiol.* 38(7): 792-803; Hansen et al. (1997) *Mol. Gen. Genet.* 254(3): 337-343; Russell et al. (1997) *Transgenic Res.* 6(2): 157-168; Rinehart et al. (1996) *Plant Physiol.* 112(3): 1331-1341; Van Camp et al. (1996) *Plant Physiol.* 112(2): 525-535; Canevaschi et al. (1996) *Plant Physiol.* 112(2): 513-524; Yamamoto et al. (1994) *Plant Cell Physiol.* 35(5): 773-778; Lam (1994) *Results Probl. Cell Differ.* 20: 181-196; Orozco et al. (1993) *Plant Mol. Biol.* 23(6): 1129-1138; Mitsuoka et al. (1993) *Proc. Natl. Acad. Sci. USA* 90 (20): 9586-9590; and Guevara-Garcia et al (1993) *Plant J.* 4(3): 495-50.

"Operably linked" means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter. DNA operably linked to a promoter is "under transcriptional initiation regulation" of the promoter. In a preferred aspect, the promoter is an inducible promoter or a developmentally regulated promoter.

20

Particular of interest in the present context are nucleic acid constructs which operate as plant vectors. Specific procedures and vectors previously used with wide success upon plants are described by Guerineau and Mullineaux (1993) (*Plant transformation and expression vectors*. In: *Plant Molecular Biology Labfax* (Croy RRD ed) Oxford, BIOS Scientific Publishers, pp 121-148. Suitable vectors may include plant viral-derived vectors (see e.g. EP-A-194809).

25

If desired, selectable genetic markers may be included in the construct, such as those that confer selectable phenotypes such as resistance to antibiotics or herbicides (e.g. kanamycin, hygromycin, phosphinotricin, chlorsulfuron, methotrexate, gentamycin, spectinomycin, imidazolinones and glyphosate).

30

Preferably said promoter is the cinnamate-4-hydroxylase (CH4) promoter, wherein C4H is an enzyme in the phenylpropanoid pathway. Alternatively said promoter is the constitutive promoter, CaMV 35S promoter.

- 5 In a further preferred embodiment of the invention the expression of said nucleic acid molecule is down-regulated to reduce glucosyltransferase activity in said cell.

In a preferred embodiment of the invention said expression is reduced by at least 10%. Preferably said activity is reduced by between 10%-99%. Preferably said activity is
10 reduced by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, or at least 90% when compared to a non-transgenic reference cell.

Preferably said down-regulation is as a result of said cell being null for a nucleic acid molecule selected from the group consisting of;

- 15 i) a nucleic acid molecule comprising a nucleic acid sequence as represented in Figure 1;
ii) a nucleic acid molecule comprising a nucleic acid sequence which hybridises to the sequence in (i) above;
iii) a nucleic acid molecule comprising a nucleic acid
20 sequences which are degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above.

In using anti-sense genes or partial gene sequences to down-regulate gene expression, a nucleotide sequence is placed under the control of a promoter in a "reverse
25 orientation" such that transcription yields RNA which is complementary to normal mRNA transcribed from the "sense" strand of the target gene. See, for example, Rothstein et al, 1987; Smith et al, (1998), Nature 334, 724-726; Zhang et al (1992) The Plant Cell 4, 1575-1588, English et al. (1996) The Plant Cell 8, 179-188. Antisense technology is also reviewed in Bourque (1995), Plant Science 105, 125-
30 149, and Flavell (1994) PNAS USA 91, 3490-3496.

Preferably said down-regulation is as a result of said cell being null for a nucleic acid molecule selected from the group consisting of;

5

- i) a nucleic acid molecule comprising a nucleic acid sequence as represented in Figure 1 and Figure 3 and/or Figure 5;
- ii) a nucleic acid molecule comprising a nucleic acid sequence which hybridises to the sequence in (i) above;
- iii) a nucleic acid molecule comprising a nucleic acid sequences which are degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above.

10 In an alternative embodiment of the invention said down-regulation is the result of said cell being null for a nucleic acid molecule comprising a nucleic acid sequence as shown in Figure 3 and Figure 5 or a nucleic acid molecule which hybridises to a nucleic acid molecule comprising a nucleic acid sequence as shown in Figure 3 and Figure 5.

15

In an alternative preferred embodiment of the invention said cell is transformed with a nucleic acid molecule comprising an expression cassette which cassette comprises a nucleic acid sequence selected from the group consisting of:

20

- i) a nucleic acid molecule comprising a nucleic acid sequence as represented in Figure 1;
- ii) a nucleic acid molecule comprising a nucleic acid sequence which hybridises to the sequence in (i) above and which glucosylates at least one monolignol;
- iii) a nucleic acid molecule comprising a nucleic acid sequences which are degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above.

25

wherein said cassette is adapted such that both sense and antisense nucleic acid molecules are transcribed from said cassette.

30 In a further preferred embodiment of the invention said cassette is provided with at least two promoters adapted to transcribe sense and antisense strands of said nucleic acid molecule.

In a further preferred embodiment of the invention said cassette comprises a nucleic acid molecule wherein said molecule comprises a first part linked to a second part wherein said first and second parts are complementary over at least part of their sequence and further wherein transcription of said nucleic acid molecule produces an RNA molecule which forms a double stranded region by complementary base pairing of said first and second parts.

In a preferred embodiment of the invention said first and second parts are linked by at least one nucleotide base. In a further preferred embodiment of the invention said first and second parts are linked by 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide bases. In a yet further preferred embodiment of the invention said linker is at least 10 nucleotide bases.

In a further preferred embodiment of the invention the length of the RNA molecule or antisense RNA is between 10 nucleotide bases (nb) and 1000nb. Preferably said RNA molecule or antisense RNA is 100nb; 200nb; 300nb; 400nb; 500nb; 600nb; 700nb; 800nb; 900nb; or 1000nb in length. More preferably still said RNA molecule or antisense RNA is at least 1000nb in length.

More preferably still the length of the RNA molecule or antisense RNA is at least 10nb; 20nb; 30nb; 40nb; 50nb; 60nb; 70nb; 80nb; or 90nb in length. Preferably still said RNA molecule is 21nb in length.

In an alternative preferred embodiment of the invention said cell is transformed with a nucleic acid molecule comprising an expression cassette(s) which cassette(s) comprises a nucleic acid sequence selected from the group consisting of:

- i) a nucleic acid molecule comprising a nucleic acid sequence as represented in Figure 1 and Figure 3 and/or Figure 5;
- iii) a nucleic acid molecule comprising a nucleic acid sequence which hybridises to the sequence in (i) above and which glucosylates at least one monolignol;

- iii) a nucleic acid molecule comprising a nucleic acid sequences which are degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above.

5 wherein said cassette is adapted such that both sense and antisense nucleic acid molecules are transcribed from said cassette.

10 In a preferred embodiment of the invention said cassette(s) comprises a nucleic molecule comprising a nucleic acid sequence as shown in Figure 3 and Figure 5 or a nucleic acid molecule which hybridises to a nucleic acid molecule comprising a nucleic acid sequence as shown in Figure 3 and Figure 5.

In a further preferred embodiment of the invention said expression cassette is part of a vector.

15 In a preferred embodiment of the invention said transgenic cell is a eukaryotic cell. Preferably said eukaryotic cell is a plant cell. Alternatively said eukaryotic cell is a yeast cell.

20 In an alternative embodiment of the invention said transgenic cell is a prokaryotic cell. Preferably said prokaryotic cell is a bacterial cell.

In a further preferred embodiment of the invention, a transgenic plant is provided comprising a transgenic cell of the invention.

25 In yet still a further preferred embodiment of the invention said plant is a woody plant selected from: poplar, eucalyptus; Douglas fir; pine; walnut; ash; birch; oak; teak; spruce. Preferably said woody plant is a plant used typically in the paper industry, for example poplar.

30 Methods to transform woody species of plant are well known in the art. For example the transformation of poplar is disclosed in US4795855 and WO9118094. The transformation of eucalyptus is disclosed in EP1050209 and WO9725434. Each of these patents is incorporated in their entirety by reference.

In a still further preferred embodiment of the invention said plant is a non-woody plant selected from the group consisting of: corn (*Zea mays*), canola (*Brassica napus*, *Brassica rapa* ssp.), alfalfa (*Medicago sativa*), rice (*Oryza sativa*), rye (*Secale cereale*), sorghum (*Sorghum bicolor*, *Sorghum vulgare*), sunflower (*Helianthus annuus*), wheat
5 (*Triticum aestivum*), soybean (*Glycine max*), tobacco (*Nicotiana tabacum*), potato (*Solanum tuberosum*), peanuts (*Arachis hypogaea*), cotton (*Gossypium hirsutum*), sweet potato (*Ipomoea batatas*), cassava (*Manihot esculenta*), coffee (*Coffea* spp.), coconut (*Cocos nucifera*), pineapple (*Ananas comosus*), citrus tree (*Citrus* spp.) cocoa (*Theobroma cacao*), tea (*Camellia sinensis*), banana (*Musa* spp.), avocado (*Persea
10 americana*), fig (*Ficus casica*), guava (*Psidium guajava*), mango (*Mangifer indica*), olive (*Olea europaea*), papaya (*Carica papaya*), cashew (*Anacardium occidentale*), macadamia (*Macadamia integrifolia*), almond (*Prunus amygdalus*), sugar beets (*Beta vulgaris*), oats, barley, vegetables and ornamentals.

15 Preferably, plants of the present invention are crop plants (for example, cereals and pulses, maize, wheat, potatoes, tapioca, rice, sorghum, millet, cassava, barley, pea, and other root, tuber or seed crops. Important seed crops are oil-seed rape, sugar beet, maize, sunflower, soybean, and sorghum. Horticultural plants to which the present invention may be applied may include lettuce, endive, and vegetable brassicas
20 including cabbage, broccoli, and cauliflower, and carnations and geraniums. The present invention may be applied in tobacco, cucurbits, carrot, strawberry, sunflower, tomato, pepper, chrysanthemum.

Grain plants that provide seeds of interest include oil-seed plants and leguminous
25 plants. Seeds of interest include grain seeds, such as corn, wheat, barley, rice, sorghum, rye, etc. Oil-seed plants include cotton, soybean, safflower, sunflower, Brassica, maize, alfalfa, palm, coconut, etc. Leguminous plants include beans and peas. Beans include guar, locust bean, fennugreek, soybean, garden beans, cowpea, mungbean, lima bean, fava bean, lentils, chickpea, etc.

30

According to a further aspect of the invention there is provided for modulating the lignin content of a plant comprising the steps of;

- i) providing a cell according to the invention,

- ii) providing conditions conducive to growth of said cell into a plantlet and optionally
- iii) determining the lignin content of said plant.

5 According to a fourth aspect of the invention there is provided a method of manufacture of paper or board from a transgenic plant exhibiting an altered lignin content comprising the steps of;

- i) pulping the transgenic wood material derived from the transgenic plant according to the invention; and
- 10 ii) producing paper from said pulped transgenic wood material.

An embodiment of the invention will now be described by example only and with reference to the following figures:

15 Figure 1 is the nucleic acid sequence of glucosyltransferase 72E1;

Figure 2 is the amino acid sequence of glucosyltransferase 72E1;

Figure 3 is the nucleic acid sequence of glucosyltransferase 72E2;

20

Figure 4 is the amino acid sequence of glucosyltransferase 72E2;

Figure 5 is the nucleic acid sequence of glucosyltransferase 72E3

25 Figure 6 is the amino acid sequence of glucosyltransferase 72E3;

Figure 7 illustrates examples of monolignols and their modification by the glucosyltransferase 72E1 and 72E2; and

30 Table 1 illustrates the activity of 72E1 with respect to monolignol substrates.

35

Materials and Methods

Glucosyltransferases activity assay

- 5 Recombinant UGT72E1 was expressed and purified from *E. coli* as described previously (Lim et al., 2001, *J. Biol. Chem.* 276, 4344-4349). The enzyme (2 µg) was incubated with 1 mM phenolic substrates, 5 mM UDP-glucose, 100 mM Tris-HCl, pH 7.0 in a total volume 200 µl. The reaction mix was incubated at 30 °C for 1 h and was analysed using HPLC subsequently.

10

HPLC analysis

Coniferyl alcohol: 10-25% acetonitrile (0.1% TFA), 306 nm

Sinapyl alcohol: 10-25% acetonitrile (0.1% TFA), 285 nm

p-coumaryl alcohol: 10-25% acetonitrile (0.1% TFA), 311 nm

- 15 coniferyl aldehyde: 10-47% acetonitrile (0.1% TFA), 311 nm

sinapylaldehyde: 10-47% acetonitrile (0.1% TFA), 280 nm

p-coumaryl aldehyde: 10-47% acetonitrile (0.1% TFA), 315 nm

Table 1

20

Substrates	Activity (area, uv x sec)	
	72E1	72E2
Coniferyl alcohol	3225766	29756923
Sinapyl alcohol	0	3339410
p-coumaryl alcohol	0	0
Coniferyl aldehyde	21950129	5068215
Sinapyl aldehyde	13655427	37002362
p-coumaryl aldehyde	9243651	2612331

CLAIMS

1. A transgenic cell wherein the genome of said cell comprises a nucleic acid molecule wherein said nucleic acid molecule is selected from the group consisting of;
- 5 i) a nucleic acid molecule comprising a nucleic acid sequence as represented in Figure 1;
- ii) a nucleic acid molecule comprising a nucleic acid sequence which hybridises to the sequence in (i) above and which glucosylates at least one monolignol;
- 10 iii) a nucleic acid molecule comprising a nucleic acid sequences which are degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above.
2. A cell according to Claim 1 wherein said aldehyde of a monolignol is selected
- 15 from the group consisting of, *p*-coumaryl aldehyde, coniferyl aldehyde and sinapyl aldehyde.
3. A cell according to Claim 2 wherein said monolignol is coniferyl alcohol.
- 20 4. A cell according to any of Claims 1-3 wherein said nucleic acid is cDNA.
5. A cell according to any of Claims 1-3 wherein said nucleic acid is genomic DNA.
- 25 6. A cell according to any of Claims 1-5 wherein said nucleic acid molecule comprises a nucleic acid sequence as shown in Figure 1.
7. A cell according to any of Claims 1-4 wherein said nucleic acid molecule consists of a nucleic acid sequence as shown in Figure 1.
- 30 8. A cell according to any of Claims 1-7 wherein said nucleic acid molecule is over expressed.

9. A cell according to Claim 8 wherein said cell over-expresses a nucleic acid molecule selected from the group consisting of:

- 5
- i) a nucleic acid molecule comprising a nucleic acid sequence as represented in Figure 1 and Figure 3 and/or Figure 5;
 - ii) a nucleic acid molecule comprising a nucleic acid sequence which hybridises to the sequence in (i) above and which glucosylates at least one monolignol;
 - 10 iii) a nucleic acid molecule comprising a nucleic acid sequences which are degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above.

10. A cell according to Claim 8 wherein said cell over-expresses a nucleic acid molecule as represented by the nucleic acid sequence shown in Figure 3 and Figure 5,
15 or a nucleic acid molecule which hybridises to a nucleic acid molecule as represented by the nucleic acid sequence in Figure 3 and Figure 5.

11. A cell according to any of Claims 1-7 wherein the expression of said nucleic acid molecule is down-regulated to reduce glucosyltransferase activity in said cell.
20

12. A cell according to Claim 11 wherein said down-regulation is as a result of said cell being null for a nucleic acid molecule selected from the group consisting of;

- i) a nucleic acid molecule comprising a nucleic acid sequence as represented in Figure 1;
- 25 ii) a nucleic acid molecule comprising a nucleic acid sequence which hybridises to the sequence in (i) above;
- iii) a nucleic acid molecule comprising a nucleic acid sequences which are degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above.

30

13. A cell according to Claim 11 wherein said down-regulation is as a result of said cell being null for a nucleic acid molecule selected from the group consisting of;

i) a nucleic acid molecule comprising a nucleic acid sequence as represented in Figure 1 and Figure 3 and/or Figure 5;

ii) a nucleic acid molecule comprising a nucleic acid sequence which hybridises to the sequence in (i) above;

iii) a nucleic acid molecule comprising a nucleic acid sequences which are degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above.

5

10

15

14. A cell according to Claim 11 wherein said down-regulation is the result of said cell being null for a nucleic acid molecule comprising a nucleic acid sequence as shown in Figure 3 and Figure 5, or a nucleic acid molecule which hybridises to a nucleic acid molecule comprising a nucleic acid sequence as shown in Figure 3 and Figure 5.

20

15. A cell according to Claim 11 wherein said cell is transformed with a nucleic acid molecule comprising an expression cassette which cassette comprises a nucleic acid sequence selected from the group consisting of:

i) a nucleic acid molecule comprising a nucleic acid sequence as represented in Figure 1;

iv) a nucleic acid molecule comprising a nucleic acid sequence which hybridises to the sequence in (i) above and which glucosylates at least one monolignol;

iii) a nucleic acid molecule comprising a nucleic acid sequences which are degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above.

25

30

wherein said cassette is adapted such that both sense and antisense nucleic acid molecules are transcribed from said cassette.

16. A cell according to Claim 15 wherein said cassette is provided with at least two promoters adapted to transcribe sense and antisense strands of said nucleic acid molecule.

17. A cell according to Claim 15 wherein said cassette comprises a nucleic acid molecule wherein said molecule comprises a first part linked to a second part wherein said first and second parts are complementary over at least part of their sequence and
5 further wherein transcription of said nucleic acid molecule produces an RNA molecule which forms a double stranded region by complementary base pairing of said first and second parts.

18. A cell according to Claim 17 wherein said first and second parts are linked by
10 at least one nucleotide base.

19. A cell according to Claim 11 wherein said cell is transformed with a nucleic acid molecule comprising an expression cassette(s) which cassette(s) comprises a nucleic acid sequence selected from the group consisting of:

- 15 i) a nucleic acid molecule comprising a nucleic acid sequence as represented in Figure 1 and Figure 3 and/or Figure 5;
- ii) a nucleic acid molecule comprising a nucleic acid sequence which hybridises to the sequence in (i) above
20 and which glucosylates at least one monolignol;
- iii) a nucleic acid molecule comprising a nucleic acid sequences which are degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above.

wherein said cassette is adapted such that both sense and antisense nucleic acid
25 molecules are transcribed from said cassette.

20. A cell according to Claim 19 wherein said cassette(s) comprises a nucleic acid molecule comprising a nucleic acid sequence as shown in Figure 3 and Figure 5 or a nucleic acid molecule which hybridises to a nucleic acid molecule comprising a
30 nucleic acid sequence as shown in Figure 3 and Figure 5.

21. A cell according to any of Claims 12-20 wherein said expression cassette is part of a vector.

22. A cell according to any of Claims 1-21 wherein said transgenic cell is a eukaryotic cell.

23. A cell according to Claim 22 wherein said cell is a plant cell.

5

24. A transgenic plant comprising a cell according to Claim 23.

25. A plant according to Claim 24 wherein said plant is a woody plant selected from: poplar; eucalyptus; Douglas fir; pine; walnut; ash; birch; oak; teak; spruce.

10

26. A method for modulating the lignin content of a plant comprising the steps of;

- i) providing a cell according to any of Claims 1-23,
- ii) providing conditions conducive to growth of said cell into a plantlet and optionally,
- iii) determining the lignin content of said plant.

15

27. A method of manufacture of paper or board from a transgenic plant exhibiting an altered lignin content comprising the steps of;

- i) pulping the transgenic wood material derived from the transgenic plant according to Claim 24 ; and
- ii) producing paper from said pulped transgenic wood material.

20

25

30

35

40

Abstract**Glucosyltransferases**

- 5 We describe transgenic cells which are transformed with nucleic acid molecules which encode glucosyltransferase polypeptides involved in phenylpropanoid biosynthesis

117

Figure 1 72E1

ATGAAGATTACAAAACCATGTGGCCATGTTGCTAGCCCCGGAATGGGCCACA
TCATCCCGGTGATCGAGCTCGGAAAACGCTTAGCTGGTTCCACGGCTTCGATGT
CACCATTTTCGTCTTGAAACCGACGCAGCCTCAGCTCAATCTCAATTCCTTAACT
CACCAGGCTGCGACGCGGCCCTTGTGATATCGTTGGCCTCCCAACGCCCGATAT
CTCCGGTTTAGTCGACCCATCAGCCTTTTTTGGGATCAAGCTCTTGGTCATGATGC
GTGAGACCATTCCTACCATCCGGTCAAAGATAGAGGAGATGCAACACAAACCAA
CGGCTCTGATCGTAGACTTGTGTGGTTGGACGCGATACCGCTCGGTGGTGAGTTC
AACATGTTGACTTATATCTTCATCGCTTCAAACGCACGTTTTCTCGCGGTGGCTTT
GTTTTCCCAACGTTGGACAAAGACATGGAAGAAGAGCACATAATCAAGAAGCA
ACCTATGGTTATGCCTGGATGTGAACCGGTTTCGGTTTGAAGATACACTTGAAACA
TTCCTTGACCCAAACAGCCAACTCTACCGGGAATTTGTTCTTTTCGGTTCGGTTT
CCCAACGTGTGATGGTATTATTGTGAATACATGGGATGATATGGAGCCCCAAACT
TTGAAATCTCTTCAAGACCCAAAGCTCTTGGGTGCAATTGCTGGTGTACCGGTTTA
TCCAATTGGTCTCTTGTCTAGACCGGTTGATCCATCTAAAACTAATCATCCGGTTT
TGGATTGGTTAAACAAACAGCCGGACGAGTCGGTACTTTACATTTTCAATTTGGAAG
CGGTGGCTCTCTCTCGGCTAAACAACCTAACCGAATTGGCTTGGGGACTTGAGATG
AGTCAGCAACGGTTCGTTTGGGTGGTTCGACCCCGGTGGACGGTTCAGCTTGCA
GTGCATATTTATCCGCTAACAGTGGTAAAATACGAGACGGTACACCTGATTATCT
CCCGGAAGGTTTTGTTAGCCGGACTCATGAGAGAGGCTTTATGGTCTCTTCTTGG
GCTCCCCAAGCGGAGATCTTGGCCACCAAGCCGTAGGTGGGTTTCTAACTCACT
GCGGTGGAAATTCGATTCTCGAGAGCGTTCGTTGGTGGCGTTCCGATGATCGCGTG
GCCACTTTTTGCGGAGCAGATGATGAACGCGACACTCCTCAACGAAGAGCTTGGC
GTTGCGCTCCGCTCTAAGAAACTACCGTCCGAGGGAGTGATTACGAGGGCGGAG
ATCGAGGCGTTGGTGAGAAAGATCATGGTGGAGGAGGAAGGTGCTGAGATGAGA
AAGAAGATAAAGAAGCTGAAAGAGACCGCTGCCGAATCGCTGAGTTGCGACGGT
GGAGTGGCGCATGAATCGTTGTCAAGAATCGCCGACGAGAGCGAGCATCTTTTGG
AGCGTGTGAGGTGCATGGCACGTGGTGCCTAG

2/7

Figure 2

MKITKPHVAMFASPGMGHIIPVIELGKRLAGSHGFDVTIFVLETDAASAQSQF
LNSPGCDAALVDIVGLPTPDISGLVDPSAFFGIKLLVMMRETIPTIRSKIEEMQH
KPTALIVDLFGLDAIPLGGFENMLTYFIASNARFLAVALFFPTLDKDMEEHHI
KKQPMVMMPGCEPVRFEDTLETFLDPNSQLYREFVPFGSVFPTCDGIIVNTWDD
MEPKTLKSLQDPKLLGRIAGVPVYPIGPLSRPVDPSKTNHPVLDWLNKQPD
VLYISFGSGGSLSAKQLTELAWGLEMSQQRFWVVRPPVDGSACSAYLSANS
GKIRDGTPDYLPEGFVSRTHRGFMVSSWAPQAEILAHQAVGGFLTHCGWNS
ILES VVGVPMLAWPLFAEQMMNATLLNEELGVAVRSKKLPSEGVITRAEIEA
LVRKIMVEEEGAEMRKKIKKKLKETAAESLSCDGGVAHESLSRIADESEHLLER
VRCMARGA

317

Figure 3 72B2

ATGCATATCA CAAAACCACA CGCCGCCCATG TTTTCCAGTC CCGGAATGGG
CCATGTGATC CCGGTGATCG AGCTTGGAAG GCGTCTCTCC GCTAACCAACG
GCTTCCACGT CACCGTCTTC GTCCCTCGAA CCGACGCAGC CTCCTCTCAA
TCCAAGTTCC TAAACTCAAC CGGCGTCCAC ATCGTCAAAC TTCCATCGCC
GGACATTTAT GGTTTAGTGG ACCCCGACGA CCATGTAGTG ACCAAGATCG
GAGTCATTAT GCGTGACGCA GTTCCAGCCC TCCGATCCAA GATCGCTGCC
ATGCATCAAA AGCCAACGGC TCTGATCGTT GACTTGTGTTG GCACAGATGC
GTTATGTCTC GCAAAGGAAT TTAACATGTT GAGTTATGTG TTTATCCCTA
CCAACGCACG TTTTCTCGGA GTTTCGATTT ATTATCCAAA TTTGGACAAA
GATATCAAGG AAGAGCACAC AGTGCAAAGA AACCCACTCG CTATACCGGG
GTGTGAACCG GTTAGGTTCC AAGATACTCT GGATGCATAT CTGGTTCCCG
ACGAACCGGT GTACCGGGAT TTTGTTCTGC ATGGTCTGGC TTACCCAAA
GCCGATGGAA TTTTGGTAAA TACATGGGA GAGATGGAGC CCAAATCATT
GAAGTCCCTT CTAAACCCAA AGCTCTTGGG CCGGTTGCT CGTGTACCGG
TCTATCCAAT CGGTCCCTTA TGCAGACCGA TACAATCATC CGAAACCGAT
CACCCGGFTT TGGATTGGTT AAACGAACAA CCGAACGAGT CCGTTCTCTA
TATCTCTTC GGGAGTGGTG GTTGTCTATC GCGGAACAG TTAAGTGAAT
TGGCGTGGG ACTCGAGCAG AGCCAGCAAC GGTTCGTATG GGTGGTTCCA
CCACCGGTG ACGGTTCTGT TTGTAGCGAG TATGTCTCGG CTAACGGTGG
TGGAACCGAA GACAACACGC CAGAGTATCT ACCGGAAGGG TTCGTGASTC
GTACTAGTGA TAGAGGTTTC GTGGTCCCTT CATGGGCCCC ACAAGCTGAA
ATCCTGTCCC ATCGGGCCGT TGGTGGGTTT TTGACCCATT GCGGTTGGAG
CTCGACGTTG GAAAGCGTCG TTGGCGGCGT TCCGATGATC GCATGGCCAC
TTTTTGCGA GCAGAATATG AATGCGGCGT TGCTCAGCGA CGAACTGGGA
ATCGCAGTCA GATTGGATGA TCCAAAGGAG GATATTTCTA GGTGGAAGAT
TGAGGCGTTG GTGAGGAAGG TTATGACTGA GAAGGAAGGT GAAGCGATGA
GAAGGAAGT GAAGAAGTTG AGAGACTCGG CGGAGATGTC ACTGAGCATT
GACGGTGGTG GTTTGGCGCA CGAGTCCCTT TGCAGAGTCA CCAAGGAGTG
TCAACGGTTT TTGGAACGTG TCGTGGACTT GTCACGTGGT GCTTAG

4/7

Figure 4 72E2

MHITKPHAAM PSSPGMGHVI PVIELGKRLS ANNGFHVTVF VLETDAASAO
SKFLNSTGVD IVKLPSFDIY GLVDEDDHVV TKIGVIMRAA VPALESKIAA
MHQKPTALIV DLFGTDALCL AKEFNMLSYV FIPTNARFLG VSIYYPNLDK
DIKEEHTVQR NPLAIPGCEP VRFEDTLDAY LVPDEFVYRD FVRHGLAYFK
ADGILVNTWE EMEPKSLKSL LNPKLLGRVA RVFVYPIGPL CRPIQSSETD
HPVLDWLNEQ PNESVLYISF GSGGCLSAKQ LTELAWGLEQ SQQRFVWVVR
PFVDGSCCSE YVSANGGGTE DNTPEYLPEG FVSRTSDRGF VVPSWAPQAE
ILSHRAVGGE LTHCGWSSTL ESVVGGVPMI AWPLFAEQNM NAALLSDELG
IAVRLDDPKE DISRWKIEAL VRKVMTEKEG EAMRRKVKKL RDSAEMSLSI
DGGGLAHESL CRVTKECQRF LERVVDLSRG A

517

Figure 5 72B3

ATGCATATCA CAAAACCACA CGCCGCCATG TTTTCCAGTC CCGGAATGGG
CCATGTCCTC CCGGTGATCG AGCTAGCTAA GCGTCTCTCC GCTAACCACG
GCTTCCACGT CACCGTCTTC GTCCCTGAAA CTGACGCAGC CTCOGTTCAG
TCCAAGCTCC TTAACCTAAC CGGTGTTGAC ATCGTCAACC TTCCATCGCC
CGACATTTCT GGCTTGGTAG ACCCAACGC CCATGTGGTG ACCAAGATCG
GAGTCATTAT GCGTGAAGCT GTTCCAACCG TCCGATCCAA GATCGTTGCC
ATGCATCAAA ACCCAACGGC TCTGATCATT GACTTGTTCG GCACAGATGC
GTTATGTCTT GCAGCGGAGT TAAACATGTT GACTTATGTC TTTATCGCTT
CCAACGCGCG TTATCTCGGA GTTTCGATAT ATTATCCAAC TTTGGACGAA
GTTATCAAAG AAGAGCACAC AGTGCAACGA AAACCGGTCA CTATACGGG
GTGTGAACCG GTTAGATTTC AAGATAATTAT GGATGCATAT CTGGTTCGG
ACGAACCGGT GTACCACGAT TTGGTTCGTC ACTGTCTGGC CTACCCAAAA
GCGGATGGAA TCTTGGTGAA TACATGGGAA GAGATGGAGC CCAATCATT
AAAGTCCCTT CAAGACCCGA AACTTTTGGG CCGGTTCGCT CGTGTACCGG
TTTATCCGGT TGGTCCGTTA TGCAGACCGA TACAATCATC CACGACCGAT
CACCCGGTTF TTGATTGGTT AAACAACAA CCAAACGAGT CGGTTCTCTA
CATTCCTTC GGGAGTGGTG GTTCTCTAAC GGCTCAACAG TTAACCGAAT
TGGCGTGGGG GCTCGAGGAG AGCCAGCAAC GGTTTATATG GGTGGTTGGA
CGGCGGTTG ACGGCTCGTC TTGCAGTGAT TATTCTCGG CTAAAGGCGG
TGTAACCAAA GACAACACGC CAGAGTATCT ACCAGAAGGG TTCGTGACTC
GTACTTGCGA TAGAGGTTTC ATGATCCCAT CATGGGCACC GCAAGCTGAA
ATCCTAGCCC ATCAGGCCGT TGGTGGGTTT TTAACACATT GTGGTTGGAG
CTCGACGTTG GAAAGCGTCC TTTGCGGCGT TCCAATGATA GCGTGGCCGC
TTTTCGCCGA GCAGAATATG AACGCGGCGT TGCTTAGCGA TGAAGTGGGA
ATCTCTGTTA GAGTGGATGA TCCAAGGAG GCGATTTCTA GGTGGAAGAT
TGAGGCGATG GTGAGGAAGG TTATGGCTGA GGACGAAGGT GAAGAGATGA
GAAGGAAAGT GAAGAAGTTC AGAGACACGG CGGAGATGTC ACTTAGTATT
CACGGTGGTG GTTCGGCGCA TGAGTCGCTT TGCAGAGTCA CGAAGGAGTG
TCAACGGTTT TTGGAATGTG TCGGGGACTT GGGACGTGGT GCTTAG


617

Figure 6 72E3

MHITKPHAAM FSSPGMGHVL FVIELAKRLS ANEGFEVTVF VLETDAASVQ
SKLLNSTGVD IVNLSPDIS GLVDPNAHVV TKIGVIMREA VPTLRSKIVA
MEQNPTALII DLFGTDALCL AAELNMLTYV FIASNARYLG VSIYYPTLDE
VIKEEETVQR KPLTIPGCEP VRFEDIMDAY LVEDEPVYHD LVRHCLAYPK
ADGILVNTWE EMEPKSLKSL QDPKLLGEVA RVPVYPVGPL CRPIQSSTED
HPVFDWLKQ PNESVLYISF GSGGSLTAQQ LTELANGLEE SQQRFIWVVR
PPVDGSSCSD YFSAXGGVTK DNTPEYLPEG FVTRTCDRGF MIPSWAPQAE
ILAHQAVGGF LTHCGWSSTL ESVLCGVPMI AWPLFABQNM NAALLSDELG
ISVRVDDPKK AISRSKIEAM VRKVMAEDEG EEMRRKVKKL RDTAEMSLSI
HGGGSAHBSL CRVTXECORF LECVGD LGRG A


7/7

p-coumaryl alcohol




(no activity)


Coniferyl alcohol




Sinapyl alcohol




p-coumaryl aldehyde



Coniferyl aldehyde



Sinapyl aldehyde



* : position for glucosylation

Figure 7

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB04/004330

International filing date: 12 October 2004 (12.10.2004)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0323813.6
Filing date: 13 October 2003 (13.10.2003)

Date of receipt at the International Bureau: 19 November 2004 (19.11.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.